A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05364073

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:13.530721+00:00

Published At

2026-03-13T00:00:00+00:00

Record Updated At

2026-03-13

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Lung Cancer", "HER2 Exon 20 Mutations", "EGFR Exon 20 Mutations", "EGFR Uncommon Mutations, Including G719X and S768I"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-03-13"

protocolSection.identificationModule.nctId

"NCT05364073"

protocolSection.identificationModule.officialTitle

"A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Non-Small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
• Metastatic Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Advanced Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• HER2 Exon 20 Mutations (protocolSection.conditionsModule.conditions)
• EGFR Exon 20 Mutations (protocolSection.conditionsModule.conditions)
• EGFR Uncommon Mutations, Including G719X and S768I (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.